title: Do CSF levels of t-Tau, p-Tau and β₁₋₄₂ amyloid correlate with dopaminergic system impairment in patients with a clinical diagnosis of Parkinson disease? A ¹²³I-FP-CIT study in the early stages of the disease.
abstract: OBJECTIVE
  To investigate the relationships among cerebrospinal fluid (CSF) levels of t-Tau, p-Tau and Aβ₁₋₄₂ amyloid peptide and (123)I-FP-CIT uptake.
  
  
  METHODS
  The study included 58 subjects (31 men and 27 women, age 67 ± 9 years) with a clinical diagnosis of Parkinson disease diagnosed according to the United Kingdom Parkinson Disease Society Brain Bank criteria. All subjects underwent a CSF assay 28 ± 3 days before (123)I-FP-CIT SPECT scanning. The relationships were evaluated by means of linear regression analysis and Pearson correlation.
  
  
  RESULTS
  Striatal (123)I-FP-CIT was positively related to both t-Tau and p-Tau CSF values with low levels of t-Tau and p-Tau being related to a low uptake of (123)I-FP-CIT. In particular, differences with higher statistical significance were found for the striatum that is contralateral to theside mainly affected on clinical examination (P<0.001) [corrected].No significant relationships were found between Aβ₁₋₄₂ amyloid peptide and (123)I-FP-CIT binding.
  
  
  CONCLUSIONS
  The results of our study suggest that the presynaptic dopaminergic system is more involved in Parkinson disease patients with lower t-Tau and p-Tau CSF values while values of Aβ₁₋₄₂ amyloid peptide seems not to be related to nigrostriatal degeneration in our series.
authors.affiliation: Department of Biomedicine and Prevention, University Tor Vergata, Viale Oxford 81, 00133, Rome, Italy, agostino.chiaravalloti@gmail.com.
authors.forename: Agostino
authors.initials: A
authors.lastname: Chiaravalloti
authors.forename: Alessandro
authors.initials: A
authors.lastname: Stefani
authors.forename: Alessandro
authors.initials: A
authors.lastname: Fiorentini
authors.forename: Annamaria
authors.initials: A
authors.lastname: Lacanfora
authors.forename: Paolo
authors.initials: P
authors.lastname: Stanzione
authors.forename: Orazio
authors.initials: O
authors.lastname: Schillaci
mesh_terms: D000368:Aged; D016229:Amyloid beta-Peptides / Q000134:cerebrospinal fluid*; D015415:Biomarkers / Q000134:cerebrospinal fluid / Q000378:metabolism; D004298:Dopamine / Q000378:metabolism*; D005260:Female; D006801:Humans; D008297:Male; D010300:Parkinson Disease / Q000134:cerebrospinal fluid* / Q000000981:diagnostic imaging*; D010446:Peptide Fragments / Q000134:cerebrospinal fluid*; D010766:Phosphorylation; D015899:Tomography, Emission-Computed, Single-Photon; D014326:Tropanes; D016875:tau Proteins / Q000134:cerebrospinal fluid* / Q000378:metabolism*
chemical_list: D016229:Amyloid beta-Peptides; D015415:Biomarkers; D010446:Peptide Fragments; D014326:Tropanes; C075222:amyloid beta-protein (1-42); D016875:tau Proteins; C087552:2-carbomethoxy-8-(3-fluoropropyl)-3-(4-iodophenyl)tropane; D004298:Dopamine